Cancer Therapy News and Research

RSS

Oncolytics begins enrollment in 2-Arm carboplatin Phase II randomized study for pancreatic cancer

Oncolytics Biotech Inc. announced today that enrollment has begun in a 2-Arm randomized Phase II study of carboplatin, paclitaxel plus REOLYSIN versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer.

17 Feb 2011

First lung cancer treatment with BSD's MicroThermX ablation system delivered at Rhode Island Hospital

BSD Medical Corporation today announced the successful delivery of its first lung cancer patient treatment with the MicroThermX® Microwave Ablation System. The treatment was conducted by Damian E. Dupuy, M.D., at The Comprehensive Cancer Center at Rhode Island Hospital in Providence, Rhode Island.

16 Feb 2011

Advaxis added to Mentor Capital Cancer Immunotherapy Index

Mentor Capital, Inc. reports that Advaxis, Inc. has been added as the newest member of the Mentor Capital Cancer Immunotherapy Index.

16 Feb 2011

CTI's fourth quarter net loss increases to $34.1 million

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the fourth quarter and year ended December 31, 2010.

16 Feb 2011

RPCI offers first FDA-approved cancer treatment vaccine

The nation's first FDA-approved cancer treatment vaccine, Provenge, is being offered for the first time in Western New York at Roswell Park Cancer Institute.

15 Feb 2011

US Oncology's PAPs help cancer patients to access high quality care

Through the continuous and tremendous growth of its patient assistance support program, US Oncology, Inc., a division of McKesson Corp. and a leading integrated oncology company, is helping cancer patients access the high quality cancer care they need. By helping patients obtain financial assistance, thousands can now afford much needed treatment and cancer therapies.

15 Feb 2011

Oncolytics' REOLYSIN/gemcitabine combination Phase 2 pancreatic cancer trial meets primary endpoint

Oncolytics Biotech Inc. today announced preliminary results from a U.S. Phase 2 clinical trial (REO 017) using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar®) in patients with advanced pancreatic cancer. The trial is being conducted at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio (CTRC).

15 Feb 2011

Researcher discovers mechanism how p53 human genome gets inactivated in cancerous cells

One of the most important genes in the human genome is called p53 and its function is to suppress tumours, according to Roger Leng, a researcher in the Faculty of Medicine & Dentistry. Leng has discovered the mechanism by which p53 is inactivated in cancerous cells, allowing tumours to grow.

15 Feb 2011

Unmet need for medical help to address sexual issues in breast, gynecologic cancer survivors

Many women who survive breast and gynecologic cancers want medical help for their sexual issues, but most do not get it. A survey of hundreds of cancer survivors, published online in the journal Cancer, confirms that more than forty percent want medical attention for their sexual health needs.

15 Feb 2011

State Roundup: Calif. adult day care; S.C.'s budget cuts; Minn. 'boomer bust'

As Gov. Jerry Brown has proposed slashing government aid for poor people, he argues that California still provides more generous benefits than many other states. … State-by-state comparisons are complicated. ... While California pays health costs for a larger share of its population, it spends less per person. It reimburses health care providers less and covers a younger, healthier group of people (Yamamura, 2/14).

14 Feb 2011

OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) to collaborate on the conduct of a randomized Phase 2 trial of ZYBRESTAT in combination with bevacizumab in patients with relapsed ovarian cancer.

14 Feb 2011

Cancer cells 'addicted' to self-preservation process

A team of investigators at The Cancer Institute of New Jersey (CINJ); Rutgers, The State University of New Jersey; and Princeton University, have determined that cancer cells are "addicted" to a self-preservation process known as autophagy. They also showed that the inhibition of that process could prove to be a valuable treatment approach for aggressive cancers. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

11 Feb 2011

Genta initiates new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer

Genta Incorporated today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer. Tesetaxel, the leading oral taxane in clinical development, will be evaluated for its use as both first- and second-line chemotherapy.

10 Feb 2011

Indiana University creates Institute for Personalized Medicine

Indiana University has announced a major commitment to research in one of health care's most promising fields with the creation of the Indiana Institute for Personalized Medicine.

10 Feb 2011

Study: 30% of older patients with vulvar cancer die from treatment complications, ICD

Research by the American Academy of Family Physicians demonstrates that vulvar cancer occurs most frequently in women age 65 to 75 years of age. Thirty percent of patients with vulvar cancer are age 70 or older, and the rate increases with age, reaching a peak of 20 per 100,000 women by 75 years of age.

10 Feb 2011

Breakthrough in cancer research can help reduce heart failure, increase survival rates

A breakthrough by scientists at Queen's University Belfast could help reduce heart failure in cancer patients around the world, and ultimately increase survival rates.

10 Feb 2011

NYBC ends emergency appeal for blood donations

Thanks to the support of blood donors – who answered the emergency call after winter snowstorms drove blood supplies to critical levels – New York Blood Center is ending its emergency appeal for blood donations and returning to its normal collection schedule. The supply of several blood types, including O-negative blood, has returned to recommended 3-5 day inventory levels.

10 Feb 2011

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

CeNeRx BioPharma, Inc., a clinical-stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced FDA approval of its IND and reported the first clinical results in humans for CXB909, a novel agent that has demonstrated utility in preclinical models of neuroprotection and neurodegenerative disorders.

9 Feb 2011

Men with high levels of CCP genes more likely to have fatal form of prostate cancer

A genetic pattern could predict how aggressive prostate cancer is before treatment, and whether the disease will come back in men who have already been treated, according to research published1 in the Lancet Oncology.

9 Feb 2011

Tower announces formation of Cancer Support Network to provide high quality of care

As part of its commitment to providing the highest quality of care to the community, Tower Hematology Oncology Medical Group has announced the formation of Tower Oncology's Cancer Support Network.

8 Feb 2011

Cancer Therapy News and Research

Oncolytics begins enrollment in 2-Arm carboplatin Phase II randomized study for pancreatic cancer

First lung cancer treatment with BSD's MicroThermX ablation system delivered at Rhode Island Hospital

Advaxis added to Mentor Capital Cancer Immunotherapy Index

CTI's fourth quarter net loss increases to $34.1 million

RPCI offers first FDA-approved cancer treatment vaccine

US Oncology's PAPs help cancer patients to access high quality care

Oncolytics' REOLYSIN/gemcitabine combination Phase 2 pancreatic cancer trial meets primary endpoint

Researcher discovers mechanism how p53 human genome gets inactivated in cancerous cells

Unmet need for medical help to address sexual issues in breast, gynecologic cancer survivors

State Roundup: Calif. adult day care; S.C.'s budget cuts; Minn. 'boomer bust'

OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

Cancer cells 'addicted' to self-preservation process

Genta initiates new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer

Indiana University creates Institute for Personalized Medicine

Study: 30% of older patients with vulvar cancer die from treatment complications, ICD

Breakthrough in cancer research can help reduce heart failure, increase survival rates

NYBC ends emergency appeal for blood donations

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

Men with high levels of CCP genes more likely to have fatal form of prostate cancer

Tower announces formation of Cancer Support Network to provide high quality of care

Your guide to microplate readers for cancer research eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News